Log in

NASDAQ:CTXR - Citius Pharmaceuticals Stock Price, Forecast & News

$0.51
-0.01 (-1.92 %)
(As of 12/12/2019 06:12 AM ET)
Today's Range
$0.47
Now: $0.51
$0.54
50-Day Range
$0.42
MA: $0.50
$0.61
52-Week Range
$0.40
Now: $0.51
$1.79
Volume109,061 shs
Average Volume142,048 shs
Market Capitalization$11.30 million
P/E RatioN/A
Dividend YieldN/A
Beta0.49
Citius Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, and prescription products. The company develops Mino-Lok, which is in Phase III clinical trials for the treatment and salvage of infected central venous catheters in patients with catheter related bloodstream infections; and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for the treatment of hemorrhoids. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CTXR
CUSIPN/A
Phone908-967-6677

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.72 per share

Profitability

Net Income$-12,530,000.00

Miscellaneous

Employees7
Market Cap$11.30 million
Next Earnings DateN/A
OptionableNot Optionable

Receive CTXR News and Ratings via Email

Sign-up to receive the latest news and ratings for CTXR and its competitors with MarketBeat's FREE daily newsletter.


Citius Pharmaceuticals (NASDAQ:CTXR) Frequently Asked Questions

What is Citius Pharmaceuticals' stock symbol?

Citius Pharmaceuticals trades on the NASDAQ under the ticker symbol "CTXR."

When did Citius Pharmaceuticals' stock split? How did Citius Pharmaceuticals' stock split work?

Shares of Citius Pharmaceuticals reverse split on Friday, June 9th 2017. The 1-15 reverse split was announced on Thursday, June 8th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 8th 2017. An investor that had 100 shares of Citius Pharmaceuticals stock prior to the reverse split would have 7 shares after the split.

What price target have analysts set for CTXR?

2 brokerages have issued 1 year price targets for Citius Pharmaceuticals' shares. Their forecasts range from $3.00 to $7.00. On average, they anticipate Citius Pharmaceuticals' share price to reach $5.00 in the next twelve months. This suggests a possible upside of 876.8% from the stock's current price. View Analyst Price Targets for Citius Pharmaceuticals.

What is the consensus analysts' recommendation for Citius Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Citius Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Citius Pharmaceuticals.

Has Citius Pharmaceuticals been receiving favorable news coverage?

News stories about CTXR stock have trended negative this week, InfoTrie reports. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Citius Pharmaceuticals earned a news impact score of -3.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Citius Pharmaceuticals.

Are investors shorting Citius Pharmaceuticals?

Citius Pharmaceuticals saw a decrease in short interest in November. As of November 29th, there was short interest totalling 250,300 shares, a decrease of 6.3% from the November 14th total of 267,100 shares. Based on an average daily trading volume, of 168,300 shares, the short-interest ratio is currently 1.5 days. Approximately 1.6% of the company's shares are sold short. View Citius Pharmaceuticals' Current Options Chain.

Who are some of Citius Pharmaceuticals' key competitors?

What other stocks do shareholders of Citius Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Citius Pharmaceuticals investors own include Progenics Pharmaceuticals (PGNX), Real Goods Solar (RGSE), SCYNEXIS (SCYX), Opko Health (OPK), Canopy Growth (CGC), Flex Pharma (FLKS), Idera Pharmaceuticals (IDRA), Melinta Therapeutics (MLNT), SenesTech (SNES) and Zynerba Pharmaceuticals (ZYNE).

Who are Citius Pharmaceuticals' key executives?

Citius Pharmaceuticals' management team includes the folowing people:
  • Mr. Leonard L. Mazur, Exec. Chairman & Sec. (Age 74)
  • Mr. Myron Z. Holubiak, Pres, CEO & Director (Age 72)
  • Mr. Jaime Bartushak, CFO, Chief Accounting Officer & Principal Financial Officer (Age 51)
  • Mr. Gary F. Talarico, Exec. VP of Operations (Age 64)
  • Mr. Andrew Scott, VP of Corp. Devel.

Who are Citius Pharmaceuticals' major shareholders?

Citius Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Sabby Management LLC (3.83%). Company insiders that own Citius Pharmaceuticals stock include Leonard L Mazur and Myron Z Holubiak. View Institutional Ownership Trends for Citius Pharmaceuticals.

Which major investors are buying Citius Pharmaceuticals stock?

CTXR stock was acquired by a variety of institutional investors in the last quarter, including Sabby Management LLC. Company insiders that have bought Citius Pharmaceuticals stock in the last two years include Leonard L Mazur and Myron Z Holubiak. View Insider Buying and Selling for Citius Pharmaceuticals.

How do I buy shares of Citius Pharmaceuticals?

Shares of CTXR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Citius Pharmaceuticals' stock price today?

One share of CTXR stock can currently be purchased for approximately $0.51.

How big of a company is Citius Pharmaceuticals?

Citius Pharmaceuticals has a market capitalization of $11.30 million. The company earns $-12,530,000.00 in net income (profit) each year or ($1.17) on an earnings per share basis. Citius Pharmaceuticals employs 7 workers across the globe.View Additional Information About Citius Pharmaceuticals.

What is Citius Pharmaceuticals' official website?

The official website for Citius Pharmaceuticals is http://www.citiuspharma.com/.

How can I contact Citius Pharmaceuticals?

Citius Pharmaceuticals' mailing address is 11 Commerce Drive First Floor, Cranford NJ, 07016. The company can be reached via phone at 908-967-6677.


MarketBeat Community Rating for Citius Pharmaceuticals (NASDAQ CTXR)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  137 (Vote Outperform)
Underperform Votes:  178 (Vote Underperform)
Total Votes:  315
MarketBeat's community ratings are surveys of what our community members think about Citius Pharmaceuticals and other stocks. Vote "Outperform" if you believe CTXR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTXR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/12/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel